RBC Capital Maintains Outperform on Amgen, Raises Price Target to $362
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza maintains an Outperform rating on Amgen (NASDAQ:AMGN) and raises the price target from $332 to $362.
August 07, 2024 | 3:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Gregory Renza maintains an Outperform rating on Amgen and raises the price target from $332 to $362.
The raised price target and maintained Outperform rating from a reputable analyst at RBC Capital is likely to positively impact Amgen's stock price in the short term as it reflects strong confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100